Clinical performance comparison of two medium cut‐off dialyzers
Detlef H. Krieter, Marieke Rüth, Horst‐Dieter Lemke, Christoph Wanner
Abstract
Abstract Introduction Medium‐cut‐off (MCO) dialyzers may beneficially impact outcomes in patients on hemodialysis. Methods In a randomized, controlled trial in maintenance hemodialysis patients, the new Nipro ELISIO‐17HX MCO dialyzer was compared to the Baxter Theranova 400 filter regarding middle molecule removal. Furthermore, the suitability of two assays for free lambda‐light chain (λFLC) detection (Freelite vs. N‐Latex) was verified. Results ELISIO‐HX achieved slightly lower reduction ratios for β 2 ‐microglobulin (71.8 ± 6.0 vs. 75.3 ± 5.8%; p = 0.001), myoglobin (54.7 ± 8.6 vs. 64.9 ± 8.7%; p < 0.001), and kappa‐FLC (62.1 ± 8.8 vs. 56.3 ± 7.7%; p = 0.021). λFLC reduction ratios were more conclusive with the Freelite assay and not different between ELISIO‐HX and Theranova (28.4 ± 3.9 vs. 38.7 ± 13.4%; p = 0.069). The albumin loss of Theranova was considerably higher (2.14 ± 0.45 vs. 0.77 ± 0.25 g; p = 0.001) and the Global Removal Score Loss alb largely inferior (30.6 ± 7.4 vs. 82.4 ± 29.2%/g; p = 0.006) to ELISIO‐HX. Conclusions The new ELISIO‐HX expands the choice of dialyzers for MCO hemodialysis.